Scientists studying a hard-to-treat form of blood cancer called acute myeloid leukemia (AML) have found that a type of treatment—immunotherapy—may help change the environment where cancer cells live, ...

Regulatory approval was supported by a statistically significant improvement in 1‑year moderate‑to‑severe cGVHD‑free survival ...

Scientists studying a hard-to-treat form of blood cancer called acute myeloid leukemia (AML) have found that a type of treatment - immunotherapy - may help change the environment where cancer cells ...

Researchers from the Alliance for Clinical Trials in Oncology have found that two targeted immunotherapy drugs lead to high remission rates and long survival with reasonable side effects for older ...

Even with treatment, the cancer often comes back. This high rate of relapse can be traced to leukemia stem cells, a small group of cells that can survive chemotherapy by hiding in the bone marrow.

Fralin Biomedical Research Institute Cancer Research Center in Washington, D.C., research scientist Gege Gui (left) led a multi-institutional collaboration on new research investigating how ...

Regulatory T cell-based immunotherapy approved for use in matched-donor HSCTs ...

Novel allogeneic T-cell-based immunotherapy reduces chronic graft-versus-host disease (GVHD) in patients with blood cancers undergoing stem cell transplantationSilver Spring, MD, July 01, 2026 (GLOBE ...

Leukemia symptoms include fatigue, weakness, chest pain, shortness of breath, bleeding, bruising, and increased infection risk due to altered blood cell counts. Recent leukemia treatment advancements ...

The results of Alliance A041703 Cohort 1, published in the Journal of Clinical Oncology, focused on treating patients aged 60 years and older with newly diagnosed B-cell acute lymphoblastic leukemia ...